Clinical Trials

This clinical trial for patients with HER2-positive endometrial cancer. Cancer cells that are making too many copies of a certain protein are called HER2. This trial is testing if adding one of two HER2-targeted drug combinations to standard chemotherapy can improve outcomes for patients with HER2-positive endometrial serous carcinoma or carcinosarcoma.

Participants are assigned to one of three groups:
Group 1: Standard treatment with paclitaxel and carboplatin.
Group 2: Standard chemotherapy plus Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk).
Group 3: Standard chemotherapy plus Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf).

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.

The trial wants to find out two things:
First, it will test if a new drug called cabozantinib is safe to give along with the usual chemotherapy drugs (methotrexate, doxorubicin, and cisplatin).
Second, it will see if adding cabozantinib to the usual chemotherapy works better than chemotherapy alone.
Cabozantinib is a medicine that helps slow down cancer growth. The doctors are hoping that adding it to the standard treatment will help fight the osteosarcoma more effectively.

Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).

This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory). Langerhans cell histiocytosis is a type of disease that occurs when the body makes too many immature Langerhans cells (a type of white blood cell). When these cells build up, they can form tumors in certain tissues and organs including bones, skin, lungs and pituitary gland and can damage them. This tumor is more common in children and young adults. DAY101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Using DAY101 may be effective in treating patients with relapsed or refractory Langerhans cell histiocytosis.

This Phase III clinical trial is for patients aged 5 to 60 years old who have been recently diagnosed with early-stage (Stage I or II) classical Hodgkin lymphoma (cHL) that hasn't been treated yet.
The study wants to see if a new treatment approach is better than the standard one. The new approach adds two immune system-boosting medicines (brentuximab vedotin and nivolumab) to regular chemotherapy and possibly radiation.
The goal is to find out if adding these extra medicines helps people survive longer, or if it causes fewer bad side effects compared to using only the standard treatment.

This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.

The primary objective of this study is to assess the effect of adjuvant treatment with olaparib on Invasive Disease-Free Survival (IDFS).
Note: This study is closed to accrual, meaning that the research team is no longer enrolling new subjects.

The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.

The investigational Vascular Covered Stent is a self-expanding, low profile, polytetrafluoroethylene encapsulated nitinol implant. It is deployed from a delivery system that provides controlled stent release.